<Header>
<FileStats>
    <FileName>20241017_10-Q-A_edgar_data_862692_0000950170-24-115377.txt</FileName>
    <GrossFileSize>311369</GrossFileSize>
    <NetFileSize>15496</NetFileSize>
    <NonText_DocumentType_Chars>60779</NonText_DocumentType_Chars>
    <HTML_Chars>128294</HTML_Chars>
    <XBRL_Chars>46896</XBRL_Chars>
    <XML_Chars>51013</XML_Chars>
    <N_Exhibits>5</N_Exhibits>
</FileStats>
<SEC-Header>
0000950170-24-115377.hdr.sgml : 20241017
<ACCEPTANCE-DATETIME>20241017171353
ACCESSION NUMBER:		0000950170-24-115377
CONFORMED SUBMISSION TYPE:	10-Q/A
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20240831
FILED AS OF DATE:		20241017
DATE AS OF CHANGE:		20241017

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CRYO CELL INTERNATIONAL INC
		CENTRAL INDEX KEY:			0000862692
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				223023093
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1130

	FILING VALUES:
		FORM TYPE:		10-Q/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40767
		FILM NUMBER:		241378344

	BUSINESS ADDRESS:	
		STREET 1:		700 BROOKER CREEK BLVD
		STREET 2:		SUITE 1800
		CITY:			OLDSMAR
		STATE:			FL
		ZIP:			34677
		BUSINESS PHONE:		813-749-2104

	MAIL ADDRESS:	
		STREET 1:		700 BROOKER CREEK BLVD
		STREET 2:		SUITE 1800
		CITY:			OLDSMAR
		STATE:			FL
		ZIP:			34677

</SEC-Header>
</Header>

 0000950170-24-115377.txt : 20241017

10-Q/A
 1
 ccel-20240831.htm
 10-Q/A

10-Q/A 

U.S. SECURITIES AND EXCHANGE COMMISSION 
 WASHINGTON D.C. 20549 
 
 FORM 
 (Amendment No. 1) 
 
 (Mark One) 
 	Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. 
 For the quarterly period ended 
 	Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. 
 For the transition period from to 
 Commission File Number 

(Exact name of Registrant as Specified in its Charter) 

(State or other Jurisdiction of Incorporation or Organization) 
 
 (I.R.S. Employer Identification No.) 

. , 

(Address of Principal Executive Offices) (Zip Code) 

(Issuer's phone number, including area code) 

(Former name, former address and former fiscal year, if changed since last report). 
 
 Securities registered pursuant to Section 12(b) of the Act: 

Title of each class 
 
 Trading Symbol(s) 
 
 Name of each exchange on which registered 

Check whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. No 
 Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files. No Not Applicable 
 Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definition of large accelerated filer, accelerated filer, small reporting company and emerging growth company in Rule 12b-2 of the Exchange Act. (Check one): 

Large accelerated filer 
 
 Accelerated filer 

Smaller reporting company 

Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 
 
 Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) 
 Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date. As of October 15, 2024 , shares of 0.01 par value common stock were outstanding. 

Item 6. Exhibits 

31.1 
 
 Certification of Co-CEO Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 

31.2 
 
 Certification of Co-CEO Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 

31.3 
 
 Certification of CFO Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 

32.1 
 
 Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. 

101.INS 
 
 Inline XBRL Instance Document 

101.SCH 
 
 Inline XBRL Taxonomy Extension Schema Document 

101.CAL 
 
 Inline XBRL Taxonomy Extension Calculation Linkbase Document 

101.DEF 
 
 Inline XBRL Taxonomy Extension Definition Linkbase Document 

101.LAB 
 
 Inline XBRL Taxonomy Extension Label Linkbase Document 

101.PRE 
 
 Inline XBRL Taxonomy Extension Presentation Linkbase Document 

104 
 
 Cover Page Interactive Data File (embedded within the Inline XBRL document) 

SIGNAT URES 
 In accordance with Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. 

Cryo-Cell International, Inc. 

/s/ David Portnoy 

David Portnoy 

Co-Chief Executive Officer 

Cryo-Cell International, Inc. 

/s/ Mark Portnoy 

Mark Portnoy 

Co-Chief Executive Officer 

Cryo-Cell International, Inc. 

/s/ Jill M. Taymans 

Jill M. Taymans 

Vice President, Finance, Chief Financial Officer 

Date: October 17,2024 
 3 

<EX-31.1>
 2
 ccel-ex31_1.htm
 EX-31.1

EX-31.1 

EXHIBIT 31.1 
 CERTIFICATION OF CO-CHIEF EXECUTIVE OFFICER 
 I, David Portnoy, certify that: 
 1. I have reviewed this quarterly report on Form 10-Q/A of Cryo-Cell International, Inc. (the Registrant ); 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 

4. The Registrant s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d 15(f)) for the Registrant and have: 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared; 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; 

(c) Evaluated the effectiveness of the Registrant s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and 

(d) disclosed in this report any change in the Registrant s internal control over financial reporting that occurred during the Registrant s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Registrant s internal control over financial reporting; 

5. The Registrant s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant s auditors and the audit committee of the Registrant s board of directors (or persons performing the equivalent functions): 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant s ability to record, process, summarize and report financial information; and 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant s internal control over financial reporting. 

Dated: October 17, 2024 

/s/ David Portnoy 

David Portnoy 

</EX-31.1>

<EX-31.2>
 3
 ccel-ex31_2.htm
 EX-31.2

EX-31.2 

EXHIBIT 31.2 
 CERTIFICATION OF CO-CHIEF EXECUTIVE OFFICER 
 I, Mark Portnoy, certify that: 
 1. I have reviewed this quarterly report on Form 10-Q/A of Cryo-Cell International, Inc. (the Registrant ); 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 

4. The Registrant s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d 15(f)) for the Registrant and have: 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared; 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; 

(c) Evaluated the effectiveness of the Registrant s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and 

(d) disclosed in this report any change in the Registrant s internal control over financial reporting that occurred during the Registrant s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Registrant s internal control over financial reporting; 

5. The Registrant s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant s auditors and the audit committee of the Registrant s board of directors (or persons performing the equivalent functions): 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant s ability to record, process, summarize and report financial information; and 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant s internal control over financial reporting. 

Dated: October 17, 2024 

/s/ Mark Portnoy 

Mark Portnoy 

</EX-31.2>

<EX-31.3>
 4
 ccel-ex31_3.htm
 EX-31.3

EX-31.3 

EXHIBIT 31.3 
 CERTIFICATION OF CHIEF FINANCIAL OFFICER 
 I, Jill M. Taymans, certify that: 
 1. I have reviewed this quarterly report on Form 10-Q/A of Cryo-Cell International, Inc. (the Registrant ); 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 

4. The Registrant s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d 15(f)) for the Registrant and have: 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared; 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; 

(c) Evaluated the effectiveness of the Registrant s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and 

(d) disclosed in this report any change in the Registrant s internal control over financial reporting that occurred during the Registrant s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Registrant s internal control over financial reporting; 

5. The Registrant s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant s auditors and the audit committee of the Registrant s board of directors (or persons performing the equivalent functions): 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant s ability to record, process, summarize and report financial information; and 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant s internal control over financial reporting. 

Dated: October 17, 2024 

/s/ Jill M. Taymans 

Jill M. Taymans 

</EX-31.3>

<EX-32.1>
 5
 ccel-ex32_1.htm
 EX-32.1

EX-32.1 

EXHIBIT 32.1 
 CERTIFICATION PURSUANT TO 
 18 U.S.C. SECTION 1350, 
 AS ADOPTED PURSUANT TO 
 SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 
 In connection with the Quarterly Report of Cryo-Cell International, Inc. (the Company on Form 10-Q/A for the quarter ended August 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the Report ), I, David Portnoy, Co-Chief Executive Officer of the Company, I, Mark Portnoy, Co-Chief Executive Officer of the Company, and I, Jill M. Taymans, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that: 
 1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Act of 1934; and 

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. 

/s/ David Portnoy 

David Portnoy 

Co-Chief Executive Officer 

October 17, 2024 

/s/ Mark Portnoy 

Mark Portnoy 

Co-Chief Executive Officer 

October 17, 2024 

/s/ Jill M. Taymans 

Jill M. Taymans 

Vice President, Finance (Chief Financial Officer) 

October 17, 2024 

</EX-32.1>

<EX-101.SCH>
 6
 ccel-20240831.xsd
 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT

</EX-101.SCH>

